Healthcare Sales & Marketing Network News: Ceptaris Therapeutics

Searching News Database: Ceptaris Therapeutics

HSMN NewsFeed - 12 Jun 2019
Zyla Life Sciences Appoints Dr. H. Jeffrey Wilkins as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 2 Jan 2014
NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indications; Raises $21.5 Million in Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 26 Aug 2013
Ceptaris Receives FDA Approval for VALCHLOR(TM) (mechlorethamine) Gel for the Treatment of Stage IA and IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma in Patients Who Have Received Prior Skin-Directed Therapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jun 2012
Ceptaris Secures $10 Million in Series D-1 Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 21 Feb 2012
Ceptaris Secures $15M in Venture Debt Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Jan 2012
Ceptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jan 2012
Yaupon Changes Name to Ceptaris Therapeutics, Inc.
Biopharmaceuticals Oncology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.